Because TCF4 has been shown to be constitutively activated by mutated β-catenin and the induction of the pro-apoptotic pathway directly leads to the reduction of TCF4 mRNA and protein levels [37], TCF4 could be a therapeutic target for anti-cancer drugs. The gene discussed is TCF4; the disease is cancer.